Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amazon

Microsoft

PepsiCo

Procter & Gamble

Sherwin-Williams

The Holy Grail for long-term investors is finding the best forever stocks that offer stability and growth potential. These stocks, known for their resilience, innovation and proven track records, are often cornerstones in portfolios.

The 7 Best Forever Stocks To Buy Now: October 2023

Bristol-Myers

Eli Lilly

McKesson

Pfizer

Walgreens

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company's common stock. The dividend is payable on December 5, 2023 to shareholders of record at the close of business on November 21, 2023. The ex-dividend date is November 20, 2023. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare.

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023

Johnson & Johnson reported third-quarter earnings on Tuesday, Oct. 18. Third-quarter results beat Wall Street's expectations on the top and bottom lines.

Is Johnson & Johnson Still a Good Dividend Stock to Buy?

Illinois Tool Works

Lowe's

Realty Income Corp

Sysco

Exxon Mobil

The most of the dividend aristocrats, or stocks that have increased their dividends annually for at least 25 consecutive years, are some of the highest-quality dividend stocks out there. However, the key word here is “most.

7 Dividend Aristocrats That Are Built to Last

Two analysts trimmed their price targets on the pharmaceutical giant. Those cuts came a day after the company's latest earnings release.

Why Johnson & Johnson Stock Flopped Today

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

Kenvue

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

Berkshire Hathaway CEO Warren Buffett has a nearly unmatched track record as a stock picker. Johnson & Johnson, a long-time Berkshire Hathaway holding, screens as a solid pick for defensive investors.

1 Warren Buffett Stock to Buy Hand Over Fist Right Now

The healthcare giant had plenty of positives in its Q3 update. However, there are several issues to be concerned about with J&J over the next few years.

Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?

Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%.  The pharmaceuticals driving its growth are Darzalex, a biologic used for multiple myeloma, and Erleada, a prostate cancer treatment, in addition to several other oncology therapies.

J&J's Medical Device Sales Feel the Side Effects of Weight-Loss Drugs

Archer-Daniels-Midland Company

Aflac

Allegion

Amgen

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Embecta Corp

Emerson Electric

Gilead Sciences

W.W. Grainger

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Southern Company

T. Rowe Price Group

Trane Technologies plc

With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of quarter months are always the big payers but it's still nice to see.

Dividend Income Update September 2023

Johnson & Johnson reported stronger-than-expected third-quarter results. It was the company's first earnings report since completing the Kenvue spin-off.

Johnson & Johnson's Sharper Focus Is Already Paying Dividends for Investors

J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.

J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off

Johnson & Johnson (NYSE:JNJ ) Q3 2023 Earnings Conference Call October 17, 2023 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer John Reed - Executive Vice President, Pharmaceuticals, R&D Joaquin Duato - Chairman and Chief Executive Officer Erik Haas - Vice President, Litigation Ahmet Tezel - Innovative Medicine and MedTech R&D Conference Call Participants David Risinger - Leerink Partners Matt Miksic - Barclays Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Josh Jennings - TD Cowen Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Danielle Antalffy - UBS Louise Chen - Cantor Fitzgerald Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript

Johnson & Johnson (JNJ) reported better-than-anticipated results and raised its guidance as pharmaceutical and medical equipment sales gained, even with demand for its COVID-19 vaccine waning.

J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows

Bank of America

Goldman Sachs

Retail Sales infer a consumer willing to spend, and the outlook for Q3 GDP is likely up somewhat on this news.

Retail Sales Hotter at +0.7%; JNJ, BAC, GS All Beat in Q3

Johnson & Johnson (NYSE: JNJ) is trending up this morning after reporting solid results for its third financial quarter. JNJ stock up on improved outlook The stock is being rewarded also because the management raised its guidance for the full year on Tuesday.

JNJ ‘was never dependent on COVID vaccine' for success: CFO Wolk

Johnson & Johnson beat third-quarter forecasts Tuesday and raised its outlook for the year. JNJ stock rose in premarket trading.

Johnson & Johnson Raises Outlook As The Health Care Bellwether Beats Views

News for Johnson & Johnson Stock (JNJ)